Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck KGaA, Darmstadt, Germany
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with RRMS according to McDonald criteria 2010
Relapse free within 30 days before Baseline data collection
Treatment with Rebif for 6 months or more prior to informed consent
Already using RebiSmart®2.0 + MSdialog™ for patient reported outcome (PRO) assessments (at least once prior to informed consent)
Females of childbearing potential must be willing to use appropriate contraception for the duration of the study
EDSS score less than (\<) 6
Written informed consent obtained prior to any protocol-required data collection
You may not be if
Participation in other studies within 30 days before Baseline
Female who is pregnant or breast feeding
Significant psychiatric symptoms that, in the opinion of the Investigator, would impact subject ability to comply with treatment (as per standard clinical practice)
Any contraindication for Interferon (IFN) beta-1a therapy as per Summary of Product Characteristics (SPC)
Administration of any Multiple Sclerosis (MS) therapy, other than Rebif, within 6 months prior to informed consent
Clareo Health | Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
